Purple Biotech Ltd.

PPBT • Biotechnology

Movimiento fuerte

PPBT-11.62%

vs. cierre anterior $1.98

$1.75

▼ -0.23 (-11.62%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$8,132.25

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.03Rentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 15 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 9 ago 2026, 12:18 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.75

Change-11.62%

Shares Out4.65K

Market Cap$8.13K

Enterprise Value$-6.42M

52W Range1.16 - 24.00

Beta-0.55

P/E-0.00

P/B0.00

P/FCF-0.00

EV/EBITDA0.84

EV/FCF0.96

Price$1.75

Change-11.62%

Shares Out4.65K

Market Cap$8.13K

Enterprise Value$-6.42M

52W Range1.16 - 24.00

Beta-0.55

P/E-0.00

P/B0.00

P/FCF-0.00

EV/EBITDA0.84

EV/FCF0.96

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.03

Current Ratio1.27

Quick Ratio1.27

Volume49.23K

Avg Volume312.08K

EPS Surprise3.71

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

66/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.03Rentabilidad débil

Analyst view

Analyst sentiment and price target

PPBT

Analyst sentiment

Based on 2 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 11/20/2015

Industria: Biotechnology

P/B i: 0.00

Deuda / Patrimonio i: 0.03

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje13 / 20

Deuda / Patrimonio: 0.03

Ratio corriente: 1.27

Ratio rápido: 1.27

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Rock Simcha

Transacción: 03/18/2026

OTRO

Cambio

+2,650,000

Precio

Not reported

Presentación

04/17/2026

Tipo

OTRO

Rock Simcha

Transacción: 03/18/2026

OTRO

Cambio

Precio

Not reported

Presentación

04/17/2026

Tipo

OTRO

Zilberberg Suzana

Transacción: 03/18/2026

OTRO

Cambio

+2,650,000

Precio

Not reported

Presentación

04/07/2026

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Rock Simcha	OTRO	+2,650,000	Not reported	03/18/2026	04/17/2026
Rock Simcha	OTRO	0	Not reported	03/18/2026	04/17/2026
Zilberberg Suzana	OTRO	+2,650,000	Not reported	03/18/2026	04/07/2026
Zilberberg Suzana	OTRO	0	Not reported	03/18/2026	04/07/2026
Agmon Ido	OTRO	+2,650,000	Not reported	03/18/2026	04/06/2026
Agmon Ido	OTRO	0	Not reported	03/18/2026	04/06/2026
Efron Gil	OTRO	+13,500,000	Not reported	03/18/2026	03/31/2026
Efron Gil	OTRO	0	Not reported	03/18/2026	03/31/2026
Schickler Michael	OTRO	+7,100,000	Not reported	03/18/2026	03/30/2026
Schickler Michael	OTRO	0	Not reported	03/18/2026	03/30/2026
Lankry Shai S	OTRO	+3,550,000	Not reported	03/18/2026	03/27/2026
Lankry Shai S	OTRO	0	Not reported	03/18/2026	03/27/2026
Gagnon Robert E.	OTRO	+2,650,000	Not reported	03/18/2026	03/18/2026
Gagnon Robert E.	OTRO	0	Not reported	03/18/2026	03/18/2026

Sobre la compañía

Purple Biotech Ltd.

Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.

Fuente - Link

Competidores

AKTX CDT DRMA FOXO MSPR PBM REVB SYRS VINC XAGE

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies

REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use. The patent allowance further expands the Company's intellectual property portfolio supporting its proprietary CAPTN-3 platform for conditionally activated multispecific antibodies.

GlobeNewsWire

Financial Review: Ionis Pharmaceuticals (NASDAQ:IONS) & Purple Biotech (NASDAQ:PPBT)

Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Purple Biotech (NASDAQ: PPBT - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. Earnings and Valuation This table compares Ionis Pharmaceuticals

Defense World

Purple Biotech (PPBT) Expected to Announce Quarterly Earnings on Wednesday

Purple Biotech (NASDAQ: PPBT - Get Free Report) will likely be announcing its results before the market opens on Wednesday, August 5th. Analysts expect Purple Biotech to announce earnings of ($0.98) per share for the quarter. Purple Biotech (NASDAQ: PPBT - Get Free Report) last announced its quarterly earnings data on Saturday, May 16th. The company reported

Defense World

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared to the non-capped variant IM1240 demonstrated anti-tumor activity across PD-1- and chemotherapy-resistant patient-derived tumor samples in head and neck, bladder, and lung cancers, with the NKG2A arm identified as a key contributor to this anti-tumor efficacy IM1240 induced immune cell structures associated with effective anti-tumor responses and a favorable prognosis in patient-derived non-small cell lung cancer (NSCLC) explants REHOVOT, Israel, June 11, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd.

Globe News Wire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-15	-3.8	-0.09	3.71
2026-03-13	-3.4	-19.85	-16.45
2025-11-14	-0.26	-0.29	-0.03
2025-08-06	-0.21	-0.4	-0.19
2025-03-10	-0.22	-0.26	-0.04
2024-11-15	-1.2	-1.37	-0.17
2024-08-16	-0.16	-1.6	-1.44
2024-05-21	-3	-3	0
2024-03-05	-3.4	-6.4	-3
2023-11-21	-4.4	-4.2	0.2
2023-08-22	-5	-4.6	0.4
2023-05-16	-7	-4.2	2.8